Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher Chiu

Showing results (81-90 of 129) with videos related to

Pageof 13
Sort By:
The Lancet. Healthy Longevity|September 13, 2022
Divergent age-related humoral correlates of protection against respiratory syncytial virus infection in older and young adults: a pilot, controlled, human infection challenge modelStephanie Ascough, Pete Dayananda, Mohini Kalyan, et al.
Haematologica|June 22, 2019
Daratumumab-based regimens are highly effective and well tolerated in relapsed or refractory multiple myeloma regardless of patient age: subgroup analysis of the phase 3 CASTOR and POLLUX studiesMaria-Victoria Mateos, Andrew Spencer, Ajay K Nooka, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 29, 2021
Evaluation of Sustained Minimal Residual Disease Negativity With Daratumumab-Combination Regimens in Relapsed and/or Refractory Multiple Myeloma: Analysis of POLLUX and CASTORHervé Avet-Loiseau, Jesus San-Miguel, Tineke Casneuf, et al.
Cytometry. Part a : the Journal of the International Society for Analytical Cytology|December 12, 2018
High-Parameter Mass Cytometry Evaluation of Relapsed/Refractory Multiple Myeloma Patients Treated with Daratumumab Demonstrates Immune Modulation as a Novel Mechanism of ActionHomer C Adams, Frederik Stevenaert, Jakub Krejcik, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 27, 2014
Induction of broadly cross-reactive antibody responses to the influenza HA stem region following H5N1 vaccination in humansAli H Ellebedy, Florian Krammer, Gui-Mei Li, et al.
Nature Communications|March 10, 2016
Erratum: RSV-specific airway resident memory CD8+ T cells and differential disease severity after experimental human infectionAgnieszka Jozwik, Maximillian S Habibi, Allan Paras, et al.
Nature Communications|December 22, 2015
RSV-specific airway resident memory CD8+ T cells and differential disease severity after experimental human infectionAgnieszka Jozwik, Maximillian S Habibi, Allan Paras, et al.
Science Immunology|February 9, 2024
Mucosal and systemic immune correlates of viral control after SARS-CoV-2 infection challenge in seronegative adultsHelen R Wagstaffe, Ryan S Thwaites, Arnold Reynaldi, et al.
Blood|September 13, 2011
A CCR4 antagonist combined with vaccines induces antigen-specific CD8+ T cells and tumor immunity against self antigensHelene Pere, Yves Montier, Jagadeesh Bayry, et al.
Blood|June 17, 2016
CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myelomaInger S Nijhof, Tineke Casneuf, Jeroen van Velzen, et al.
Pageof 13

Showing results (81-90 of 129) with videos related to

Sort By:
Pageof 13
The Lancet. Healthy Longevity|September 13, 2022
Divergent age-related humoral correlates of protection against respiratory syncytial virus infection in older and young adults: a pilot, controlled, human infection challenge modelStephanie Ascough, Pete Dayananda, Mohini Kalyan, et al.
Haematologica|June 22, 2019
Daratumumab-based regimens are highly effective and well tolerated in relapsed or refractory multiple myeloma regardless of patient age: subgroup analysis of the phase 3 CASTOR and POLLUX studiesMaria-Victoria Mateos, Andrew Spencer, Ajay K Nooka, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 29, 2021
Evaluation of Sustained Minimal Residual Disease Negativity With Daratumumab-Combination Regimens in Relapsed and/or Refractory Multiple Myeloma: Analysis of POLLUX and CASTORHervé Avet-Loiseau, Jesus San-Miguel, Tineke Casneuf, et al.
Cytometry. Part a : the Journal of the International Society for Analytical Cytology|December 12, 2018
High-Parameter Mass Cytometry Evaluation of Relapsed/Refractory Multiple Myeloma Patients Treated with Daratumumab Demonstrates Immune Modulation as a Novel Mechanism of ActionHomer C Adams, Frederik Stevenaert, Jakub Krejcik, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 27, 2014
Induction of broadly cross-reactive antibody responses to the influenza HA stem region following H5N1 vaccination in humansAli H Ellebedy, Florian Krammer, Gui-Mei Li, et al.
Nature Communications|March 10, 2016
Erratum: RSV-specific airway resident memory CD8+ T cells and differential disease severity after experimental human infectionAgnieszka Jozwik, Maximillian S Habibi, Allan Paras, et al.
Nature Communications|December 22, 2015
RSV-specific airway resident memory CD8+ T cells and differential disease severity after experimental human infectionAgnieszka Jozwik, Maximillian S Habibi, Allan Paras, et al.
Science Immunology|February 9, 2024
Mucosal and systemic immune correlates of viral control after SARS-CoV-2 infection challenge in seronegative adultsHelen R Wagstaffe, Ryan S Thwaites, Arnold Reynaldi, et al.
Blood|September 13, 2011
A CCR4 antagonist combined with vaccines induces antigen-specific CD8+ T cells and tumor immunity against self antigensHelene Pere, Yves Montier, Jagadeesh Bayry, et al.
Blood|June 17, 2016
CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myelomaInger S Nijhof, Tineke Casneuf, Jeroen van Velzen, et al.
Pageof 13